Ex vivo expansion of human mesenchymal stem cells in defined serum-free media
- PMID: 22645619
- PMCID: PMC3356989
- DOI: 10.1155/2012/123030
Ex vivo expansion of human mesenchymal stem cells in defined serum-free media
Abstract
Human mesenchymal stem cells (hMSCs) are presently being evaluated for their therapeutic potential in clinical studies to treat various diseases, disorders, and injuries. To date, early-phase studies have indicated that the use of both autologous and allogeneic hMSCs appear to be safe; however, efficacy has not been demonstrated in recent late-stage clinical trials. Optimized cell bioprocessing protocols may enhance the efficacy as well as safety of hMSC therapeutics. Classical media used for generating hMSCs are typically supplemented with ill-defined supplements such as fetal bovine serum (FBS) or human-sourced alternatives. Ideally, culture media are desired to have well-defined serum-free formulations that support the efficient production of hMSCs while maintaining their therapeutic and differentiation capacity. Towards this objective, we review here current cell culture media for hMSCs and discuss medium development strategies.
Figures




References
-
- Horwitz EM, Le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: the international society for cellular therapy position statement. Cytotherapy. 2005;7(5):393–395. - PubMed
-
- Horwitz EM, Maziarz RT, Kebriaei P. MSCs in Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation. 2011;17(1):S21–S29. - PubMed
-
- Prockop DJ. “Stemness" does not explain the repair of many tissues by mesenchymal stem/multipotent stromal cells (MSCs) Clinical Pharmacology and Therapeutics. 2007;82(3):241–243. - PubMed
-
- Le Blanc K, Ringdén O. Immunomodulation by mesenchymal stem cells and clinical experience. Journal of Internal Medicine. 2007;262(5):509–525. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources